Vericel Corporation (VCEL)
VCEL Stock Price Chart
Explore Vericel Corporation interactive price chart. Choose custom timeframes to analyze VCEL price movements and trends.
VCEL Company Profile
Discover essential business fundamentals and corporate details for Vericel Corporation (VCEL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Feb 1997
Employees
357.00
Website
https://vcel.comCEO
Dominick C. Colangelo
Description
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
VCEL Financial Timeline
Browse a chronological timeline of Vericel Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.04, while revenue estimate is $72.69m.
Earnings released on 7 May 2026
EPS came in at -$0.12 surpassing the estimated -$0.15 by +20.00%, while revenue for the quarter reached $68.43m , beating expectations by +7.46%.
Earnings released on 26 Feb 2026
EPS came in at $0.45 matching the estimated $0.45, while revenue for the quarter reached $92.92m , beating expectations by +2.14%.
Earnings released on 6 Nov 2025
EPS came in at $0.10 surpassing the estimated -$0.02 by +600.00%, while revenue for the quarter reached $67.50m , missing expectations by -27.15%.
Earnings released on 31 Jul 2025
EPS came in at -$0.01 surpassing the estimated -$0.04 by +75.00%, while revenue for the quarter reached $63.24m , missing expectations by -2.06%.
Earnings released on 8 May 2025
EPS came in at -$0.23 falling short of the estimated -$0.09 by -155.56%, while revenue for the quarter reached $52.60m , missing expectations by -18.84%.
Earnings released on 27 Feb 2025
EPS came in at $0.38 surpassing the estimated $0.31 by +22.58%, while revenue for the quarter reached $75.38m , beating expectations by +29.69%.
Earnings released on 7 Nov 2024
EPS came in at -$0.02 surpassing the estimated -$0.05 by +60.00%, while revenue for the quarter reached $57.91m , missing expectations by -25.73%.
Earnings released on 1 Aug 2024
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $52.66m , missing expectations by -4.56%.
Earnings released on 8 May 2024
EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%, while revenue for the quarter reached $51.28m , beating expectations by +4.51%.
Earnings released on 29 Feb 2024
EPS came in at $0.26 surpassing the estimated $0.17 by +52.94%, while revenue for the quarter reached $65.00m , beating expectations by +1.67%.
Earnings released on 8 Nov 2023
EPS came in at -$0.08 surpassing the estimated -$0.13 by +38.46%, while revenue for the quarter reached $45.58m , beating expectations by +0.95%.
Earnings released on 2 Aug 2023
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $45.92m , beating expectations by +2.09%.
Earnings released on 10 May 2023
EPS came in at -$0.16 falling short of the estimated -$0.13 by -23.08%, while revenue for the quarter reached $41.02m , beating expectations by +8.31%.
Earnings released on 23 Feb 2023
EPS came in at $0.12 surpassing the estimated $0.04 by +238.98%, while revenue for the quarter reached $52.69m , missing expectations by -0.35%.
Earnings released on 9 Nov 2022
EPS came in at -$0.14 falling short of the estimated -$0.12 by -16.67%, while revenue for the quarter reached $38.55m , missing expectations by -3.39%.
Earnings released on 3 Aug 2022
EPS came in at -$0.19 falling short of the estimated -$0.13 by -46.15%, while revenue for the quarter reached $37.05m , missing expectations by -3.39%.
Earnings released on 4 May 2022
EPS came in at -$0.15 matching the estimated -$0.15, while revenue for the quarter reached $36.07m , beating expectations by +5.16%.
Earnings released on 24 Feb 2022
EPS came in at $0.09 falling short of the estimated $0.14 by -35.71%, while revenue for the quarter reached $47.59m , missing expectations by -2.86%.
Earnings released on 9 Nov 2021
EPS came in at -$0.11 falling short of the estimated -$0.03 by -305.31%, while revenue for the quarter reached $34.51m , missing expectations by -10.61%.
Earnings released on 4 Aug 2021
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%, while revenue for the quarter reached $39.52m , beating expectations by +7.77%.
VCEL Stock Performance
Access detailed VCEL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
